Synchronous Diagnosis of Multiple Myeloma, Breast Cancer, and Monoclonal B-Cell Lymphocytosis on Initial Presentation by A. Vennepureddy, V. Motilal Nehru, Y. Liu, F. Mohammad, J. P. Atallah

“…Here we report an unusual case of concomitant existence of multiple myeloma, breast cancer, and monoclonal B-cell lymphocytosis on initial presentation. …”
Get full text

Bilateral Atypical Femoral Fractures in a Patient with Multiple Myeloma Treated with Intravenous Bisphosphonate Therapy by Ichiro Tonogai, Tomohiro Goto, Daisuke Hamada, Toshiyuki Iwame, Shinji Yoshioka, Takahiko Tsutsui, Yuichiro Goda, Hiroshi Egawa, Koichi Sairyo

“…Here we present a patient with bilateral atypical femoral fractures and multiple myeloma treated with intravenous bisphosphonate therapy.…”
Get full text

Bone Marrow Neutrophils of Multiple Myeloma Patients Exhibit Myeloid-Derived Suppressor Cell Activity by Julia Petersson, Sandra Askman, Åsa Pettersson, Stina Wichert, Thomas Hellmark, Åsa C. M. Johansson, Markus Hansson

“…In this study, we tested the hypothesis that NDGs from blood and bone marrow of multiple myeloma (MM) patients have the ability to suppress T-cells, as MDSC. …”
Get full text

Treatment of Coexisting Chronic Neutrophilic Leukemia and Light Chain Multiple Myeloma with Hydroxyurea, Bortezomib, and Dexamethasone by Evelyn Taiwo, Huiying Wang, Robert Lewis

“…The patient was diagnosed with chronic neutrophilic leukemia (CNL) associated with light chain multiple myeloma, complicated by a subdural hemorrhage. …”
Get full text

Detection of new single nucleotide polymorphisms in plasma cells carcinoma (myeloma) by polymerase chain reaction–single strand conformation polymorphism and sequencing technical m... by Sarah K. Obayes, Sabah H. Enayah, Shaimaa A. Al-Oubaidy, Rana A. Ghaleb

Subjects: “…multiple myeloma…”
Get full text

The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen by Quane Zhang, Yifan Wang, Wenting Shi, Yue Chen, Zhengmei He, Liang Yu, Chunling Wang

Subjects: Get full text

Use of disease modifying anti-rheumatic drugs and risk of multiple myeloma in US Veterans with rheumatoid arthritis by Kate Tokareva, Alexander C. Peterson, Aaron Baraff, Sarah P. Chung, Jennifer Barton, Joshua F. Baker, Bryant R. England, Ted R. Mikuls, Nicholas L. Smith, David G. Coffey, Noel S. Weiss, Namrata Singh

Subjects: Get full text

Outcomes of Idecabtagene Vicleucel Therapy in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience by Aaron Trando, Farid Ghamsari, Philip Yeung, Caitlin Costello, Ila Saunders, Ah-Reum Jeong

Subjects: Get full text

Development of Multiple Myeloma of the IgA Type in a Patient with Cold Agglutinin Disease: Transformation or Coincidence? by Øystein Sefland, Ulla Randen, Sigbjørn Berentsen

“…For years, she remained asymptomatic apart from the hemolytic anemia until eventually she developed multiple myeloma (MM) of the IgAλ phenotype. Prior to the development of MM, her hemolytic anemia responded to rituximab monotherapy. …”
Get full text

A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast by Qianru Hou, Xinyang Li, Huanxin Ma, Di Fu, Aijun Liao

Subjects: Get full text

Evaluation of plasma cell sorting methods in multiple myeloma patients: flow cytometry versus magnetic beads by Yu Jeong Choi, Jaeguk Choi, Yehyun Kang, Saeam Shin, Seung-Tae Lee, Jong Rak Choi

Subjects: Get full text

Dyspnea, Massive Effusion and Lytic Rib Lesion as Initial Presentation of Multiple Myeloma in a Young Man by Mohammed H AlShati, Ramesh Kumar, Shreeram Kannan

“…Multiple myeloma, a disorder commonly encountered in elderly patients, represents a malignant proliferation of plasma cells that primarily affects bone marrow. …”
Get full text

A Nomogram Based on Circulating Inflammatory Factors for Predicting Prognosis of Newly Diagnosed Multiple Myeloma Patients by Wang M, Yue X, Ding Y, Cai Z, Xiao H, Huang H, He J

Subjects: “…multiple myeloma…”
Get full text

Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects by Ada Alice Dona, Theophilus Tandoh, Lokesh Nigam, Mahmoud Singer, Enrico Caserta, Mariam Murtadha, Yinghui Zhu, Milad Moloudizargari, Preeti Sharma, Ottavio Napolitano, Janet Winchester, Arnab Chowdhury, Alex Pozhitkov, James F. Sanchez, Hawa Vahed, Guido Marcucci, Matt Coffey, Gerard Nuovo, Douglas W. Sborov, Flavia Pichiorri, Craig C Hofmeister

Subjects: Get full text

A review on the potential of Bruton’s tyrosine kinase (Btk) inhibitor – Ibrutinib for treatment of Multiple Myeloma (MM) by Sze-Ting Bong, Lydia Ngiik-Shiew Law, Jodi Woan-Fei Law

“… Multiple myeloma (MM) is characterized by the over-production of monoclonal plasma cells that eventually become malignant in the bone marrow. …”
Get full text

Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries by Anas Hamad, Shereen Elazzazy, Ruba Y. Taha, Hani Osman, Sana Alblooshi, Islam Elkonaissi, Mustaqeem A. Siddiqui, Khalil Al-Farsi, Mohammed Al Lamki, Sali Emara, Gihan H. Elsisi

“…**Background:** The second most common hematologic cancer worldwide is multiple myeloma (MM), with incidence and mortality rates that have more than doubled over the past 30 years. …”
Get full text

5‐Hydroxymethylcytosine Profiles of cfDNA in Urine as Diagnostic, Differential Diagnosis and Prognostic Markers for Multiple Myeloma by Weiwei Xie, Xuehui Li, Hangyu Chen, Jinlin Chu, Lei Zhang, Bo Tang, Wenrong Huang, Linlin Li, Jian Lin, Yujun Dong

Subjects: Get full text

Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia by P. Joy Ho, Hang Quach, M. Hasib Sidiqi, M. Hasib Sidiqi, Cindy H. Lee, Jason Butler, Andrew Spencer, Kenneth Micklethwaite, Kenneth Micklethwaite, Kenneth Micklethwaite, Kenneth Micklethwaite, Jingya Li, Elissa Cusson, Robert Bagnall, Simon J. Harrison

Subjects: Get full text

Targeting Caveolin‐1 in Multiple Myeloma Cells Enhances Chemotherapy and Natural Killer Cell‐Mediated Immunotherapy by Dewen Zhan, Zhimin Du, Shang Zhang, Juanru Huang, Jian Zhang, Hui Zhang, Zhongrui Liu, Eline Menu, Jinheng Wang

Subjects: Get full text

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma by Manisha Bhutani, Myra Robinson, David Foureau, Shebli Atrash, Barry Paul, Fei Guo, Jason M. Grayson, Anna Ivanina-Foureau, Mauricio Pineda-Roman, Cindy Varga, Reed Friend, Christopher J. Ferreri, Xhevahire Begic, Sarah Norek, Tiffany Drennan, Michelle B. Anderson, James T. Symanowski, Peter M. Voorhees, Saad Z. Usmani

“…Abstract: In newly diagnosed multiple myeloma (NDMM), measurable residual disease (MRD) status is prognostically important, but its role in treatment decisions remains unclear. …”
Get full text